Tesofensine 500mcg x30 Tablets
Tablet-Form Tesofensine for Oral Appetite Suppression Research
Same Tesofensine triple monoamine reuptake inhibitor in tablet form for oral administration appetite and weight loss research protocols.
Tablet-Form Tesofensine for Oral Appetite Suppression Research
Tablet format Tesofensine for researchers preferring pressed tablet delivery over capsule form. Same compound, dose, and quantity as the capsule variant.
As one of the most studied compounds in the metabolic & fat loss research space, Tesofensine has attracted sustained scientific interest across Oral weight loss research, Tablet formulation preference studies. Peer-reviewed evidence indicates that same compound and dose as capsule variant, which has positioned Tesofensine as a reference standard for researchers exploring oral weight loss research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Tesofensine Documented Benefits: 1 Documented Mechanisms
Tablet Formulation
Pressed tablet format for oral Tesofensine appetite suppression research.
How Tesofensine Works: Molecular Mechanism & Pathway
Same triple monoamine reuptake inhibition (SERT/DAT/NET) mechanism.
The 1 primary research pathways identified for Tesofensine — Tablet Formulation — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that tablet form for alternative oral delivery, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Tesofensine's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Tesofensine is routinely studied alongside Semaglutide and Tirzepatide in metabolic & fat loss-focused compound panels. Researchers investigating oral weight loss research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that 99%+ purity has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Tesofensine research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Same compound and dose as capsule variant
- Tablet form for alternative oral delivery
- 99%+ purity
Ideal For
- Oral weight loss research
- Tablet formulation preference studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Tesofensine. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Same compound and dose as capsule variant
Tablet form for alternative oral delivery
99%+ purity
Third-Party Verified Every Batch
Each vial of Tesofensine is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
